Physician profile
Dana M Bonezzi
NPI 1255331542
$4,947.50
in general payments reported to CMS, 2019-2025
49 companies · $885 in 2025
The $885 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $322 · 2021: $728 · 2022: $667 · 2023: $663 · 2024: $890 · 2025: $885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,437.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,064.88 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $526.87 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $386.58 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $357.74 | 2019-2025 | |
| Radius Health, INC. | $232.40 | 2019-2025 | Tymlos |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.33 | 2019-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $190.53 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $171.16 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.02 | 2019-2025 | Jardiance, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $137.42 | 2020-2023 | Hyqvia |
| Astellas Pharma US INC | $123.12 | 2019-2025 | Veozah |
| Merck Sharp & Dohme LLC | $115.93 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Abbott Laboratories | $106.68 | 2022-2025 | Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $92.53 | 2021-2024 | |
| Amarin Pharma, INC. | $87.89 | 2019-2020 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $77.81 | 2025 | Voquezna |
| Seqirus USA INC | $70.59 | 2022-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Xeris Pharmaceuticals, INC. | $69.94 | 2023-2025 | Gvoke Hypopen |
| Merz North America, INC. | $65.02 | 2022 | |
| Allergan, INC. | $51.59 | 2019-2022 | |
| Glaxosmithkline, LLC. | $48.99 | 2021-2025 | Shingrix, Arexvy |
| Kowa Pharmaceuticals America, INC. | $45.50 | 2020-2021 | |
| Optinose US, INC. | $40.41 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $39.45 | 2019 | |
| Medtronic, INC. | $36.60 | 2022-2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $36.30 | 2024 | Auvelity |
| Amneal Pharmaceuticals LLC | $33.94 | 2021-2025 | Unithroid |
| Jazz Pharmaceuticals INC. | $28.28 | 2021 | |
| Dexcom, INC. | $27.15 | 2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $27.15 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.74 | 2022-2023 | |
| Grifols USA, LLC | $25.97 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.60 | 2019-2024 | Eliquis |
| Exact Sciences Corporation | $23.61 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $23.52 | 2021 | |
| Madrigal Pharmaceuticals | $22.64 | 2025 | Rezdiffra |
| Dynavax Technologies Corporation | $19.50 | 2023 | Heplisav-B |
| Hologic Sales and Service, LLC | $18.98 | 2024 | Aptima |
| Pulmonx Corporation | $18.55 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Mannkind Corporation | $17.12 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.96 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $15.68 | 2019 | |
| Alfasigma USA, INC. | $13.78 | 2021 | |
| Bardy Diagnostics, INC. | $13.00 | 2022 | |
| Avanir Pharmaceuticals, INC. | $11.89 | 2020 | |
| Mayne Pharma Commercial LLC | $10.16 | 2023 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Bonezzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.